UChicago and Evelo Biosciences sign licensing deal

 

CAMBRIDGE, Mass., April 7, 2016 — Evelo Biosciences and the University of Chicago announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize a microbiome-based cancer immunotherapy. The cancer therapy, developed in the laboratories of UChicago researcher Thomas Gajewski, employs select gut microbes to boost the immune system’s attack on cancer cells and improve the efficacy of anti-cancer drugs.

Subscribe to get the latest news